Sécurité à long terme du guselkumab chez les patients atteints de maladie psoriasique : Analyse intégrée de onze études cliniques de phase II/III sur le psoriasis et le rhumatisme psoriasique
Drug Saf 2023;47(1)39–57 doi:10.1007/s40264-023-01361-w
Data gathered from 11 phase 2 and phase 3 trials have shown that guselkumab has a favourable safety profile in treating psoriatic disease. The data were gathered from 4399 patients over 10787 patient years. In the placebo-controlled periods, guselkumab showed a similar safety profile to placebo, and this remained consistent and stable in the non-placebo controlled preiods.